Medical Management of Marfan Syndrome
40:34-42:42
I think one, there a couple of things that I think, are important that is I need to emphasize that when we looked specifically at beta blockers we found that patients with beta blockers had exactly the same, we found no evidence for difference in patients who are on beta blockers. Now that strongly implies to us that the effects of these medications are similar in patients who take beta blockers to, to those who don't take beta blockers implying that the effects of angiotensin receptor blockers are similar to those who are taking beta blockers to are not taking beta blockers, so that implies that the effects are likely to be additive, so in other words the effects are likely to be independent of beta blockers.
強調しておかなければならないのは、β遮断薬を飲んでいた患者さんでも、ARBの効果に差は見られなかったということです。つまり、β遮断薬を飲んでいるかどうかに関わらず、ARBの効果は同等であったことから、ARBには付加的な効果があると言えそうです。言い換えると、ARBには、β遮断薬には依存しない独立した効果があることが期待できるということです。
And the other thing is that we, we, we, the one thing that we did find that was, that was, that was different is that the, the effects of angiotensin receptor blockers were, were different in, in patients who were on, who had FBN1 mutations, so there were some patients included in the trials who did not have FBN1 mutations and when we looked at those patients we found that we did find evidence for heterogenity for the FBN1 mutations, so patients who had FBN1 mutations at baseline were more likely to have an effect of angiotensin receptor blockers. Angiotensin receptor blockers were, you know, were particularly likely to be effective in those patients. Now that's not saying if you don't have an FBN1 mutation the ARBs won't work. They may well work but, but the ARBs had a particularly strong effect in FBN1 mutations and what that means is that, that strongly reinforces our, our belief that the angiotensin receptor blockers are effective in, in Marfan syndrome because you would really expect the drug to be most effective in people with ARB with FBN1 mutations.
その他に明らかになったことは、FBN1変異のある患者さんとFBN1変異のない患者さんとでは、ARBの効果に違いが見られたということです。FBN1変異のある患者さんの方が、ARBの効果が高くなるように思われました。FBN1変異がないからといってARBの効果を得られないというわけではないのですが、FBN1変異があるとより強い効果を得られたということです。FBN1変異がある患者さんでARBの効果が最大限に発揮されることが期待できることから、マルファン症候群においてARBが有効であるという我々の考えを裏付けてくれる結果となりました。
The Marfan Foundation did not participate in the translation of these materials and does not in any way endorse them. If you are interested in this topic, please refer to our website, Marfan.org, for materials approved by our Professional Advisory Board.
The Marfan Foundation は、当翻訳には関与しておらず、翻訳内容に関してはいかなる承認も行っておりません。このトピックに興味をお持ちの方は、Marfan.org にアクセスし、当協会の専門家から成る諮問委員会が承認した内容をご参照ください。
